Quantitative assessment of serum hepatitis B e antigen, IgM hepatitis B core antibody and HBV DNA in monitoring the response to treatment in patients with chronic hepatitis B

被引:14
|
作者
Bernard, F [1 ]
Raymond, G [1 ]
Willems, B [1 ]
Villeneuve, JP [1 ]
机构
[1] UNIV MONTREAL,HOP ST LUC,CTR RECH CLIN ANDRE VIALLET,DIV HEPATOL,MONTREAL,PQ H2X 1P1,CANADA
关键词
HBeAg; HBV; DNA; hepatitis B;
D O I
10.1046/j.1365-2893.1997.00055.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Virological response to treatment of chronic hepatitis B is defined as the loss of serum hepatitis B virus DNA (HBV DNA) and hepatitis B e antigen (HBeAg). The quantitative measurement of HBV DNA is useful for monitoring and predicting the response to therapy with interferon-alpha (IFN-alpha). In this study, we evaluated whether quantitative measurement of serum HBeAg and IgM antibody to hepatitis B core antigen (HBcAb) could also be used in this manner. Using a microparticle-capture enzyme immunoassay (IMx), a standard curve of fluorescence rate vs HBeAg concentration was constructed to provide quantitative results. The IgM HBcAb index was also measured using a microparticle enzyme immunoassay and serum HBV DNA was measured by a solution hybridization assay. We studied 48 patients who were initially positive for HBeAg and HBV DNA and who were treated with IFN-alpha 2b. Their sera were serially evaluated for HBeAg concentration, and results were compared with HBV DNA levels. In the 14 patients who responded to IFN, similar disappearance curves were observed with good intraindividual correlation between the levels of the two markers, In the 34 non-responders, HBeAg levels decreased during treatment but never became negative; HBV DNA levels also decreased during treatment and became transiently undetectable in six patients, falsely suggesting treatment success, The IgM HBcAb index paralleled changes in alanine aminotransferase (ALT) concentration and did not provide additional information. Multiple logistic regression indicated that baseline ALT and HBeAg concentrations were independent predictors of the response to treatment. and the addition of neither HBV DNA nor IgM HBcAb improved the model. We conclude that quantitative measurement of HBeAg provides information similar to that of HBV DNA in monitoring and predicting the response to treatment; this technique could be readily adaptable to clinical laboratories.
引用
收藏
页码:265 / 272
页数:8
相关论文
共 50 条
  • [31] ANTIBODY TO HEPATITIS-B CORE ANTIGEN IN CHRONIC ACTIVE HEPATITIS
    BORIES, P
    COURSAGET, P
    GOUDEAU, A
    DEGOTT, C
    MAUPAS, P
    BENHAMOU, JP
    BRITISH MEDICAL JOURNAL, 1978, 1 (6110): : 396 - 397
  • [32] Trial of lamivudine in hepatitis B surface antigen carriers with persistent hepatitis B core IgM antibody
    Ali, HY
    SAUDI MEDICAL JOURNAL, 2003, 24 (09) : 996 - 999
  • [33] ROLE OF IGM ANTIBODY TO HEPATITIS-B CORE ANTIGEN IN THE DIAGNOSIS OF HEPATITIS-B EXACERBATIONS
    MELS, GC
    BELLATI, G
    LEANDRO, G
    BRUNETTO, MR
    VICARI, O
    PIANTINO, P
    BORZIO, M
    ANGELI, G
    IDEO, G
    BONINO, F
    ARCHIVES OF VIROLOGY, 1993, : 203 - 211
  • [34] Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B
    Wai-Kay Seto
    Danny Ka-Ho Wong
    James Fung
    Ivan Fan-Ngai Hung
    John Chi-Hang Yuen
    Teresa Tong
    Ching-Lung Lai
    Man-Fung Yuen
    Hepatology International, 2013, 7 : 119 - 126
  • [35] Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B
    Seto, Wai-Kay
    Wong, Danny Ka-Ho
    Fung, James
    Hung, Ivan Fan-Ngai
    Yuen, John Chi-Hang
    Tong, Teresa
    Lai, Ching-Lung
    Yuen, Man-Fung
    HEPATOLOGY INTERNATIONAL, 2013, 7 (01) : 119 - 126
  • [36] Quantitative Hepatitis B Surface Antigen and Hepatitis B e Antigen Titers in Prediction of Treatment Response to Entecavir
    Lee, Jung Min
    Ahn, Sang Hoon
    Kim, Hyon Suk
    Park, Hana
    Chang, Hye Young
    Kim, Do Young
    Hwang, Seong Gyu
    Rim, Kyu Sung
    Chon, Chae Yoon
    Han, Kwang-Hyub
    Park, Jun Yong
    HEPATOLOGY, 2011, 53 (05) : 1486 - 1493
  • [37] Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients
    Hadziyannis, Stephanos J.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (06) : 777 - 786
  • [38] IGM ANTIBODY AGAINST HEPATITIS-B CORE ANTIGEN
    URQUHART, GED
    DUNKERLEY, RA
    BRITISH MEDICAL JOURNAL, 1983, 287 (6406): : 1719 - 1719
  • [39] Detection of hepatitis B virus DNA in serum is rare in the absence of hepatitis B surface antigen: impacts for detection and monitoring of chronic hepatitis B
    Trevillyan, Janine M.
    Dennison, Amanda
    Jenney, Adam
    Spelman, Denis
    PATHOLOGY, 2014, 46 (01) : 69 - 71
  • [40] Expression of Hepatocyte Hepatitis B Core Antigen and Hepatitis B Surface Antigen as a Marker in the Management of Chronic Hepatitis B Patients
    Yim, Sun Young
    Kim, Tae Hyung
    Jun, Suh Sang
    Kim, Eun Sun
    Keum, Bora
    Seo, Yeon Seok
    Yim, Hyung Joon
    Jeen, Yoon Tae
    Chun, Hoon Jai
    Lee, Hong Sik
    Um, Soon Ho
    Kim, Chang Duck
    Won, Nam Hee
    Ryu, Ho Sang
    GUT AND LIVER, 2017, 11 (03) : 417 - 425